Assembly Biosciences Inc
Research Assembly Biosciences Inc (ASMB) on Bullrun: market cap USD 701.31M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerASMB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 701.31M
- Financial periodQ1 2026
- RevenueUSD 8.21M
- Net income-USD 6.38M
- Free cash flow-USD 22.12M
Valuation Snapshot
latest market cap is USD 701.31M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 72.30M | -USD 6.12M | -USD 41.16M | n/a | -0.55 | USD 58.45M | USD 2.63M | USD 206.75M |
| FY2024 | USD 28.52M | -USD 40.18M | -USD 51.15M | n/a | -6.69 | USD 38.34M | USD 3.09M | USD 33.36M |
| FY2023 | USD 7.16M | -USD 61.23M | USD 22.49M | n/a | -13.38 | USD 19.84M | USD 2.34M | USD 41.10M |
| FY2022 | USD 0 | -USD 93.09M | -USD 84.57M | n/a | -23.08 | USD 52.42M | USD 5.08M | USD 82.66M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 701.31M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 539.24M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 117.67M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 53.95M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 63.41M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 112.12M | n/a | n/a | n/a |
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Assembly Biosciences Inc's market cap?
Assembly Biosciences Inc's market capitalization is USD 701.31M.
What does Assembly Biosciences Inc do?
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.